Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Advances in Neurodegenerative Diseases
share announcement

Advances in Neurodegenerative Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".

Deadline for manuscript submissions: closed (15 April 2023) | Viewed by 6363

Special Issue Editors

Prof. Dr. Miguel D'Haeseleer

E-Mail Website
Guest Editor
1. Center for Neurosciences, Vrije Universiteit Brussel, NEUR, Brussels, Belgium
2. Department of Neurology, Universitair Ziekenhuis Brussel, Brussels, Belgium
3. Nationaal Multiple Sclerosis Centrum, Melsbroek, Belgium
Interests: multiple sclerosis; biomarkers; telemedicine; sports-related concussion; neuroimaging
Prof. Dr. Jeroen Van Schependom

E-Mail Website
Guest Editor
1. Center for Neurosciences, Vrije Universiteit Brussel, AIMS, Brussels, Belgium
2. Department of Electronics and Informatics (ETRO), Vrije Universiteit Brussel, Brussels, Belgium
Interests: multiple sclerosis; Alzheimer's disease; biomarkers; magnetoencephalography; neuromodulation

Special Issue Information

Dear Colleagues,

Neurological conditions are the leading cause of disability across the globe, currently affecting almost 15% of the worldwide population. Absolute patient numbers have substantially risen over the past 30 years and (on top of that) the burden of chronic neurodegenerative disorders is expected to at least double over the next two decades. This evolution is particularly due to a substantial expansion of the aging population. Leading instances such as the World Health Organization and the United Kingdom’s national health service have already dropped the alarming quotes that “available resources for neurological services are insufficient in most countries of the world compared with global need for neurological care” and that “neurological services are not sustainable in their current form and redesign is needed”. We therefore want to dedicate this Special Issue to the challenging viewpoint that pushing boundaries in the field of neurology will be necessary to avoid a total overflow of that particular healthcare section, taking into account the above considerations. Research aimed at (a) improving our pathophysiological understanding, (b) outlining new strategies for disease prevention/modification/curation, (c) permitting early diagnosis/detection of disease progression, and (d) facilitating care delivery in chronic neurodegenerative disorders is deemed as essential to succeed in such a mission and defines the scope of this Special Issue. We welcome papers that demonstrate recent advances within this context, particularly those exploring innovative hypotheses based on a solid conceptual framework. Authors are encouraged to report negative yet meaningful findings as well.

Prof. Dr. Miguel D'Haeseleer
Prof. Dr. Jeroen Van Schependom
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neurodegeneration
  • innovation
  • pathophysiology
  • prevention
  • treatment
  • diagnosis
  • biomarkers
  • management

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Other

6 pages, 226 KiB  
Editorial
Advances in Neurodegenerative Diseases
by Jeroen Van Schependom and Miguel D’haeseleer
J. Clin. Med. 2023, 12(5), 1709; https://doi.org/10.3390/jcm12051709 - 21 Feb 2023
Cited by 26 | Viewed by 2909
Abstract
Neurological disorders are the leading cause of physical and cognitive disability across the globe, currently affecting approximately 15% of the worldwide population [...] Full article
(This article belongs to the Special Issue Advances in Neurodegenerative Diseases)

Research

Jump to: Editorial, Other

14 pages, 1345 KiB  
Article
Nanoporous Membranes for the Filtration of Proteins from Biological Fluids: Biocompatibility Tests on Cell Cultures and Suggested Applications for the Treatment of Alzheimer’s Disease
by Thomas Gabriel Schreiner, Bogdan Ionel Tamba, Cosmin Teodor Mihai, Adam Lőrinczi, Mihaela Baibarac, Romeo Cristian Ciobanu and Bogdan Ovidiu Popescu
J. Clin. Med. 2022, 11(19), 5846; https://doi.org/10.3390/jcm11195846 - 01 Oct 2022
Cited by 3 | Viewed by 1567
Abstract
Background: Alzheimer’s disease has a significant epidemiological and socioeconomic impact, and, unfortunately, the extensive research focused on potential curative therapies has not yet proven to be successful. However, in recent years, important steps have been made in the development and functionalization of nanoporous [...] Read more.
Background: Alzheimer’s disease has a significant epidemiological and socioeconomic impact, and, unfortunately, the extensive research focused on potential curative therapies has not yet proven to be successful. However, in recent years, important steps have been made in the development and functionalization of nanoporous alumina membranes, which might be of great interest for medical use, including the treatment of neurodegenerative diseases. In this context, the aim of this article is to present the synthesis and biocompatibility testing of a special filtrating nano-membrane, which is planned to be used in an experimental device for Alzheimer’s disease treatment. Methods: Firstly, the alumina nanoporous membrane was synthesized via the two-step anodizing process in oxalic acid-based electrolytes and functionalized via the atomic layer deposition technique. Subsequently, quality control tests (spectrophotometry and potential measurements), toxicity, and biocompatibility tests (cell viability assays) were conducted. Results: The proposed alumina nanoporous membrane proved to be efficient for amyloid-beta filtration according to the permeability studies conducted for 72 h. The proposed membrane has proven to be fully compatible with the tested cell cultures. Conclusions: The proposed alumina nanoporous membrane model is safe and could be incorporated into implantable devices for further in vivo experiments and might be an efficient therapeutic approach for Alzheimer’s disease. Full article
(This article belongs to the Special Issue Advances in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

Other

Jump to: Editorial, Research

8 pages, 1449 KiB  
Case Report
Pontocerebellar Hypoplasia Type 1D: A Case Report and Comprehensive Literature Review
by Ivana Dabaj, Adnan Hassani, Lydie Burglen, Leila Qebibo, Anne-Marie Guerrot, Stéphane Marret, Abdellah Tebani and Soumeya Bekri
J. Clin. Med. 2022, 11(15), 4335; https://doi.org/10.3390/jcm11154335 - 26 Jul 2022
Cited by 3 | Viewed by 1269
Abstract
Pontocerebellar hypoplasia (PCH) is an autosomal recessive, neurodegenerative disorder with multiple subtypes leading to severe neurodevelopmental disabilities. PCH type 1 D is linked to alterations in the EXOSC9 gene. EXOSC9 is a component of the RNA exosome, an evolutionarily conserved ribonuclease complex essential [...] Read more.
Pontocerebellar hypoplasia (PCH) is an autosomal recessive, neurodegenerative disorder with multiple subtypes leading to severe neurodevelopmental disabilities. PCH type 1 D is linked to alterations in the EXOSC9 gene. EXOSC9 is a component of the RNA exosome, an evolutionarily conserved ribonuclease complex essential for RNA degradation and processing. The clinical phenotype is characterized by cerebellar and pontine hypoplasia associated with motor neuronopathy. To date, nine patients have been reported in the literature with PCH1D. We report the case of an infant with PCH type 1D due to two variants in the EXOCS9 gene (NM_001034194.1: c.41T>C-p.Leu14Pro) and a novel variant (c.643C>T-p.Arg212*). This report thoroughly reviews the literature PCH1D and highlights the crucial role of the exosome in cellular homeostasis. Full article
(This article belongs to the Special Issue Advances in Neurodegenerative Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop